Comparing SG&A Expenses: Johnson & Johnson vs Viridian Therapeutics, Inc. Trends and Insights

SG&A Expenses: A Tale of Two Companies

In the world of corporate finance, Selling, General, and Administrative (SG&A) expenses are a crucial indicator of a company's operational efficiency. This analysis compares the SG&A trends of two distinct entities: Johnson & Johnson, a healthcare giant, and Viridian Therapeutics, Inc., a burgeoning biotech firm.

Johnson & Johnson: Stability Amidst Change

From 2014 to 2023, Johnson & Johnson's SG&A expenses have shown remarkable stability, averaging around $21 billion annually. Despite minor fluctuations, the company's expenses have remained within a 15% range, reflecting its robust financial management and consistent market presence.

Viridian Therapeutics: A Growth Story

In contrast, Viridian Therapeutics has experienced a dramatic increase in SG&A expenses, skyrocketing from $7.8 million in 2014 to nearly $95 million in 2023. This represents a staggering 1,100% growth, indicative of the company's aggressive expansion and investment in its operational capabilities.

This comparison highlights the diverse strategies and growth trajectories of established versus emerging companies in the healthcare sector.